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Expression of peroxiredoxin 1 and 4 promotes human
lung cancer malignancy
Hong Jiang1,2, Lisha Wu1,2, Murli Mishra1,2, Hedy A Chawsheen1,2, Qiou Wei1,2
Graduate Center for Toxicology, 2The Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA
1

Received July 10, 2014; Accepted August 12, 2014; Epub September 6, 2014; Published September 15, 2014
Abstract: Members of the Peroxiredoxin (Prx) family are major cellular antioxidants that scavenge hydrogen peroxide and play essential roles in oxidative stress and cell signaling. 2-Cys Prxs, including Prx1, 2, 3 and 4, have been
indicated in multiple oncogenic signaling pathways and thus may contribute to various processes of cancer development. The significance of 2-Cys Prxs in lung cancer development and their biological function in signal transduction
have not been fully investigated. In this study we analyzed the expression of 2-Cys Prxs in lung cancer, and examined
their levels of expression in a variety of cell lines established from human lung normal or cancer tissues. We found
that 2-Cys Prxs, in particular, Prx1 and Prx4, were preferentially expressed in cell lines derived from human lung
cancer. Through isoform specific knockdown of individual Prx, we demonstrated that Prx1 and Prx4 (but not Prx3)
were required for human lung cancer A549 cells to form soft agar colony and to invade through matrigel in culture.
Knockdown of Prx1 or Prx4 significantly reduced the activation of c-Jun and repressed the AP-1 mediated promoter
activity. In mouse xenograft models, knockdown of Prx4 in A549 cells reduced subcutaneous tumor growth and
blocked metastasis formation initiated through tail vein injection. Moreover, overexpression of Prx1 or Prx4 further
enhanced the malignancy of A549 cells both in culture and in mouse xenografts in vivo. These data provide an indepth understanding of the contribution of Prx1 and Prx4 to lung cancer development and are of importance for
future development of therapeutic methods that targeting 2-Cys Prxs.
Keywords: Peroxiredoxin, lung cancer, tumor invasion and metastasis, cell signaling

Introduction
Peroxiredoxins (Prxs), or thioredoxin-dependent
peroxidases, are originally discovered as cellular antioxidants with peroxidase activity. They
scavenge H2O2 to reduce oxidative stress and
to protect the inactivation of multiple cellular
enzymes including proteins such as glutamine
synthetase [1]. There are six isoforms of Prxs in
mammals. Based on the number and position
of Cysteine residues involved in the peroxidase
reaction, they are classified into three subgroups, i.e., 2-Cys, atypical 2-Cys and 1-Cys
Prxs. The 2-Cys Prxs, including Prx1, 2, 3 and 4,
are the predominant Prxs in mammalian cells
[2]. Most Prxs are considered as ubiquitously
expressed in various tissues and organs, and
they varies in their subcellular locations, such
as cytoplasm (Prx1, 2 and 6), nucleus (Prx1),
mitochondria (Prx3, 5 and 6), peroxisomes
(Prx5), endoplasmic reticulum (Prx4), or even

secreted into extracellular matrix in certain
type of cells (Prx4) [3, 4]. Due to these variations and their structure characteristics, members of the Prx family may have non-redundant,
distinct intracellular functions. For example,
expression and activation of Prx1 are required
for the growth and proliferation of human mammary epithelial cells [5]. Prx1 also interacts with
oncogenic protein c-Abl to inhibit its tyrosine
kinase activity [6]. Prx 2 is a negative regulator
of platelet-derived growth factor (PDGF) receptor signaling, and depletion of Prx2 results in
increased cell proliferation and migration in
response to PDGF in mouse fibroblasts and
human muscle cells [7]. Prx2 can also function
as a negative regulator of NF-κB signaling in
mouse fibroblasts [8]. Prx3 is a target of c-Myc
activation in rat fibroblasts and is required for
Myc-mediated cell proliferation and transformation [9]. Prx4 also acts as a negative regulator of NF-κB activation in HeLa cells [10]. These

Peroxiredoxins in lung cancer
studies reveal that, in addition to be scavengers and mediators of hydrogen peroxide signaling, members of the Prx family involve not
only cellular response to oxidative stress but
also various physiological or pathological processes. Therefore, understanding the contribution and molecular basis of Prxs in cell signal
transduction may be of important value for the
development of novel strategies to prevent or
treat human disease.
Previous studies report that certain Prxs are
aberrantly activated and expressed in a variety
of human cancer, including breast cancer (Prx
1, 2 and 3) [11], lung cancer (Prx1, 3 and 4) [12,
13], bladder cancer (Prx1 and 6) [14], thyroid
cancer (Prx1) [15] and oral squamous cell carcinoma (Prx1) [16]. However, the role of Prxs in
tumorigenesis and cancer progression has not
been fully investigated and understood. For
example, the role of Prx1 in human cancer is
still controversial in that it can either function
as a tumor suppressor or a pro-oncogenic factor, depending on the cellular context. There
are several lines of evidence support that Prx1
functions as a tumor suppressor. Firstly, elevated expression of Prx1 in Myc-transformed fibroblasts significantly reduces anchorage-independent colony formation and tumorigenesis in
a mouse xenograft model [17]. Secondly, Prx1
knockout cells are much more susceptible to
Ras transformation [18]. Thirdly, genetic loss of
Prx1 in mice leads to spontaneous tumor formation in multiple organs [19]. On the other
hand, the pro-oncogenic role of Prx1 in tumorigenesis and cancer progression is also well
documented in literature. For example, the levels of Prx1 in specimens of bladder cancer
have been found to be significantly higher than
normal adjacent tissue, and the increased
expression of Prx1 is associated with worse
clinical staging, higher rate of recurrence and
poor prognosis [14]. Expression of Prx1 in
breast cancer facilitates cancer cell survival
from oxidative stress induced cell death and
promotes cancer cell malignancy [20, 21]. The
pro-survival effect of Prxs may be attributed to
its function as a molecular chaperone to
enhance resistance to stress as demonstrated
in yeast and various mammalian cells [22, 23].
The exact role of other 2-Cys Prxs in human
cancer development is also not conclusive.
Therefore, a systematic evaluation of Prxs may
be critical for the understanding of their biological significance. In particular, the study of 2-Cys
446

Prxs should be accomplished under the specific context of certain types of human cancer.
Lung cancer is the leading cause of cancerrelated mortality in USA and worldwide. Although significant progress has been made over
the past decade in the early detection and combined treatment of lung cancer, the five-year
survival rate of patients with advanced lung
cancer is less than 20% (cancer statistics,
WHO). With more than fifty histological variants, lung cancer is extremely heterogeneous
and adenocarcinoma accounts for more than
40% of its overall incidence. In this study, we
examined the expression of 2-Cys Prxs in
human lung cancer and explored the functional
significance of each isoform of 2-Cys Prxs
under the context of lung adenocarcinoma. Our
data shed light on the differential function of
individual member of the Prx family in lung cancer development and we identified the unique
contribution of Prx1 and Prx4 in lung cancer
development and intracellular signal transduction. Our findings may provide novel insights for
the understanding of human lung cancer
pathogenesis.
Materials and methods
Cell lines
HEK293T cells and all other cell lines were
commercially obtained from NCI repository or
ATCC. Three immortalized cell lines established
from lung normal epithelium were used, including BEAS-2B (immortalized by SV40 T antigen),
NL20 (immortalized by SV40 T antigen) and
Nuli-1 (immortalized by HPV-E6/7 and hTERT).
Two cell lines established from lung small cell
carcinoma were used, including NCI-H69 and
NCI-H82 cells. Three cell lines established from
lung squamous cell carcinoma were used,
including NCI-H520 (from primary tumor), NCIH226 and SK-MES-1(from pleural effusion).
Three cell lines established from lung adenocarcinoma were used, including A549 (from primary tumor), NCI-H2030 (from lymph node
metastasis) and NCI-H2122 (from pleural effusion). Cells were cultured in provider’s suggested culture medium in an atmosphere of 5% CO2
at 37°C with 80~85% relative humidity.
Cell lysis and western blotting
Cultured cells were lysed in RIPA lysis buffer in
the presence of proteinase inhibitors. Proteins
Am J Cancer Res 2014;4(5):445-460
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were separated on a 4-12% gradient gel and
transferred to PVDF membrane. Western blot
was performed using standard protocol.
Primary antibodies used include, rabbit antiPrx1, 2 and 4 (Abcam), mouse anti-β-actin
(Sigma-Aldrich), mouse anti-Prx3, c-Jun, and
c-Myc (Santa Cruz), phosphor-c-Jun (p-63 and
p-73) (Cell Signaling). Western blotting was performed following standard procedure.
Lentiviral ShRNA knockdown of Prx and establishment of stable knockdown cell lines
Strictly controlled ShRNA-based knockdown
experiments were designed and performed
according to previous published suggestions
[24]. All ShRNA constructs including MISSION®
pLKO.1-puro control vector (vector control), MISSION® Non-Target shRNA (ShNT) and ShRNAs
specifically targeting either Prx1 (ShPrx1), 3
(ShPrx3), or 4 (ShPrx4) were commercially obtained (Sigma-Aldrich) and all sequences were
confirmed by commercial sequencing. Lentiviral
particles expressing ShRNAs were produced in
HEK293T cells using the provider’s plasmid
packaging system and Fugene 6 transfection
reagent following suggested transfection and
virus production procedures. The titer of viruscontaining medium was determined by measuring the level of p24 using the ELISA and Lenti-X
GoStix kits (Clontech). To establish stable knockdown, A549 cells were infected with lentiviral
particles at a multiplicity of infection (MOI) around 10 in all experiments. Cells were maintained in puromycin containing medium to establish stable cells.
Cloning of human 2-Cys Prxs into lentiviral expression vector and establishment of overexpressing stable cells
To clone human Prx1, 2, 3 and 4, the total
mRNAs of cultured HEK293T cells were extracted and purified following commercial kit protocol (Qiagen). Reverse transcriptase PCR
(RT-PCR) was performed using gene specific
primer and SuperScript™ reverse transcriptase
kit (Invitrogen). The coding region of Prx gene
was first cloned into the BamH I/Xho I sites of
the pCDNA3.1-Myc vector to generate expression plasmid that encodes c-Myc tagged fusion
protein. The coding sequences were confirmed
by DNA sequencing and fusion protein expression was verified by western blot. The validated
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coding sequences of the fusion protein were
then transferred into pLVX-IRES-Puro vector for
expression in lentiviral vectors using restriction
enzyme digestion and T4 DNA ligase. For lentivirus production, Fugene 6 and Clontech’s lentiviral packaging system were used to produce
infectious particles that expressing pLVX-IRESPuro empty vector (vector control) or c-Myc
tagged Prx. A549 cells were then infected and
maintained in puromycin containing medium as
described above for stable cell selection.
Colony formation in soft agar and transwell
matrigel cell invasion assay
For colony formation experiment, cells were
suspended in 0.3% agar and 15,000 cells/well
were seeded into 6-well plate pre-coated with
1.0 ml of 0.6% agar. Medium was changed
every 5 days for four weeks. The number and
size of colonies were examined and data were
obtained by analyzing with Image J software.
Transwell matrigel invasion assays using BD
invasion chamber were performed following the
manufacturer’s suggested protocol with 10%
serum containing medium as chemo-attractants. Invaded cells were stained by DiffQuikTM staining and images were taken under
microscope (X4). Numbers of invaded cells
were counted using the Image J software.
Proteome profiler human phospho-kinase array
The antibody based array kit, which is capable
of simultaneously measuring the levels of 46
phosphorylated proteins (all are kinase substrates) in duplicates on the same membrane,
was commercially obtained (R&D Systems).
Cells were cultured in 100 mm2 dishes and
starved for 24 hours, followed by stimulation
with or without 10% serum-containing medium
for 15 minutes. Cells were then harvested in
RIPA lysis buffer and 700 μg of cell lysates were
used for kinase array following the manufacturer’s suggested protocol. All array membranes were processed at the same time under
the same conditions, and results were obtained
by exposing membranes to a single X-ray film
with exactly the same duration of exposure
time. The intensity of each spot representing
individual phosphorylated protein was determined using Image J software. The relative spot
intensity was obtained by normalizing with the
Am J Cancer Res 2014;4(5):445-460
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Figure 1. mRNA expression of 2-Cys Prxs in human lung normal and cancer tissues from published microarrays.
Data were summarized using the Oncomine database (www.oncomine.com). A: Microarray results from Garber M.E.,
et al, PNAS USA 98:13784~9. Category and number of samples included: 0, normal lung (n = 6); 1, large cell lung
carcinoma (n = 4); 2, lung adenocarcinoma (n = 42); 3, small cell lung carcinoma (n = 5); 4, squamous cell lung carcinoma (n = 16). B: Microarray results from Bhattacharjee A., et al, PNAS USA 98:13790~5. Category and number
of samples included: 0, normal lung (n = 17); 1, lung adenocarcinoma (n = 139); 2, lung carcinoid tumor (n = 20);
3, small cell lung carcinoma (n = 6); 4, squamous cell lung carcinoma (n = 21).

intensity of the internal positive control on each
membrane.
The AP-1 luciferase reporter activity assay
A549 cells cultured in 96-well plate were transiently transfected with an AP-1 firefly luciferase reporter construct and a control renila
luciferase construct using Lipofectamine 2000.
Luciferase activities were measured at 48 hours after transfection using a dual luciferase assay kit (Promega) and a luminometer. Relative
luciferase unit (RLU) was determined as the
ratio of firefly luciferase to renila luciferase value.
Subcutaneous or tail-vein injection of A549
cells into SCID mice
The protocol for mouse xenograft experiments
was reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC). All
animal procedures were conducted following
the Policy on Humane Care and Use of Laboratory Animals, and Guidelines of the Animal
Care and Laboratory Animal Welfare (NIH). A
double-blind experimental design was applied
to eliminate potential subjective bias on protocol execution and data collection. Briefly, severe combined immunodeficiency (SCID) female
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mice at 5-week old were commercially obtained
(NCI). Mice were exposed to food and water ad
libitum and hosted in a 12/12 (hr/hr) light-dark
cycle. At the age of 6-week, mice were randomly separated into six groups to receive either
A549 ShNT, ShPrx4 or MycPrx4 cells. A total of
5 × 105 cells/mouse (in 100 μl of PBS) were
injected either subcutaneously or through tailvein. The growth of tumor in subcutaneous
injection was measured with a calibre every
other day, until the diameter at one dimension
was equal or larger than 1.0 cm. Groups of
mice injected with tumor cells through tail-vein
were all euthanized at 8 weeks after injection
due to the deterioration of health in the group
receiving MycPrx4 cells. Primary tumors (subcutaneous injection) and mouse lung (tail-vein
injection) were fixed in 4% paraformaldehyde
and stored in 70% ethanol, and proceeded with
standard paraffin-embedding, sectioning, H&E
staining and histopathological examination.
Statistical analysis
Quantitative data were
_ presented as means ±
standard deviation ( x ± sd). Data were analyzed with indicated statistical methods using
GraphPad Prism (Version 5.04). For calculation
of the p value, parameters of two-tailed, 95%
confidence interval were used for all analysis. A
Am J Cancer Res 2014;4(5):445-460
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Figure 2. Differential expression of 2-Cys Prxs in various cell lines and knockdown of individual Prx in human lung
adenocarcinoma A549 cells. (A) Expression of 2-Cys Prxs in cell lines established from human lung normal epithelium or different types of lung cancer. Cell lines were originally derived from: 1lung normal epithelium; 2small cell
carcinoma; 3squamous cell carcinoma; 4adenocarcinoma; *cancer metastasis. For each cell line, cells were lysed in
RIPA buffer at the concentration of 1× 107 cell/ml and equal volume of lysates were loaded to the gel for Western
blot. (B-D) Knockdown of endogenous Prx1 (B), Prx3 (C) or Prx4 (D) in A549 cells using isoform specific ShRNAs
targeting the correspondent protein coding regions. Two sets of unique ShRNA (indicated by the number in the parenthesis) were used for each specified Prx target. The endogenous Prx levels were measured by Western blot from
triplicate dishes of stable cells established by lentivrial infection and antibiotic selection. Note that knockdown of
targeted Prx does not interfere with the expression of other isoforms of 2-Cys Prxs.

p value of less than 0.05 is considered statistically significant.
Results
Differential expression of Prxs in human lung
cancer and cell lines
To date there are no reports in the literature
that simultaneously evaluate the transcript and
protein levels of 2-Cys Prxs in human lung cancer. Therefore we first examined the published
repository of gene expression profiling for Prxs
using Oncomine database. By focusing on the
human lung cancer microarray data, we identified and summarized the expression profiling of
Prx1, 2, 3 and 4 from at least two independent
reports based on the array of patient specimens. Analysis of the first study [25] revealed
that Prx1, 2 and 4 were highly expressed in
tumors of lung adenocarcinoma and squamous
cell carcinoma (SCC) when compared with
those of normal lung epithelium or small/large
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cell carcinoma (Figure 1A); whereas increased
expression of Prx3 was mainly found in tumor
samples of lung adenocarcinoma. Analysis of
the second study [26] revealed a very similar
finding of increased Prxs in human lung adenocarcinoma and SCC, but with variations in normal lung epithelium (Figure 1B).
To facilitate the study of Prxs in human lung
cancer, we asked whether Prxs are differentially expressed in established cell lines of human
lung normal epithelium or various tumor types.
Western blot was used to measure the endogenous protein levels of Prxs in a total of eleven
cell lines (Figure 2A). We found that Prx1 was
expressed in all cell lines, and the levels of Prx1
were relatively low in normal cell lines (BEAS2B,
NL-20 and Nuli-1), medium in cell lines of small
cell carcinoma (H69 and H82) and relatively
high in cell lines of lung SCC (H520, H226 and
SKMES) and adenocarcinoma (A549, H2030
and H2122). Moreover, Prx2 was relatively low

Am J Cancer Res 2014;4(5):445-460
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Figure 3. Knockdown of Prx1 or Prx4 in A549 cells abolishes their ability of to form anchorage independent colonies in soft agar and represses their capability of invading through matrigel. A, B: Anchorage independent colony
formation in soft agar; C, D: Transwell cell invasion assay. Compared to wildtype parental A549 (Wt) or ShNT cells,
*p<0.05 (n = 6, t test).

in normal cell lines and much higher in cell lines
of small cell carcinoma and SCC. However, in
some lung cancer cell lines including SKMES,
A549 and H2030 cells, the levels of Prx2 was
below the limit of detection or absent. On the
other hand, Prx3 was found to be universally
expressed in all cell lines tested at relatively
high levels except lower expression was found
in one of the normal cell lines (NL-20). Two of
three normal cell lines (except Nuli-1) have rela450

tively low expression of Prx4, and higher expression of Prx4 was found in cell lines of small cell
carcinoma, SCC (except SKMES) and adenocarcinoma. Taken together, these data indicate
that there’s an overall trend of higher expression of Prx1, 2 and 4 in cell lines of small cell
carcinoma and SCC compared with those of
normal cell lines, whereas in lung adenocarcinoma, the levels of Prx1 and 4 appear to be
consistently higher than those of normal cells.
Am J Cancer Res 2014;4(5):445-460
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Figure 4. Overexpression of Prx1 or Prx4 in A549 cells enhances their ability to form anchorage independent colonies in soft agar and increase their capability of invading through matrigel. (A) The protein coding regions of human
Prx1, Prx2, Prx3 or Prx4 gene in HEK293T cells were reverse transcribed and amplified by PCR, and then cloned
into the pCDNA3.1-Myc vector for protein expression; (B) Myc tagged Prx1, 2, 3 or 4 expression in A549 stable cells;
(C-F) Anchorage independent colony formation in soft agar (C, D) and transwell invasion assay (E, F) using cells with
stably overexpression of individual Prx.

Knockdown of Prx1 or Prx4 in A549 cells represses anchorage independent colony formation and matrigel invasion
A549 cells were chosen for the following experiments because there were no detectable,
endogenous levels of Prx2 expression, which
simplifies our efforts to characterize the contribution of individual Prx in these cells. A set of
four different ShRNA constructs targeting the
distinctive regions of the transcript of either
Prx1, 2 or 3, were tested for their efficiency to
knockdown the endogenous protein expression
by lentiviral infection. After initial evaluation of
knockdown efficiency in HEK293T cells, we
selected two ShRNAs that target different cod451

ing regions of either Prx1, 3 or 4 with relatively
higher efficiency to establish stable cells in
A549. Our efforts of establishing stable knockdown cells were successful and we had stable
cells completely depleted of Prx1 (Figure 2B),
Prx3 (Figure 2C) or Prx4 (Figure 2D). Although
2-Cys Prxs share commonly conserved
sequences and structural motifs, our ShRNA
knockdown was very specific in that the ShRNA
had knockdown effect only to the targeted Prx
but had no off-targets effects to other Prx isoforms. The phenotypical features of these stable cells were then compared with control cells
expressing a non-target ShRNA (ShNT cells).
We found that knockdown of Prx1 or Prx4 led to
the reduction of anchorage independent colony
Am J Cancer Res 2014;4(5):445-460
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Figure 5. Knockdown of Prx4 represses, whereas overexpression of Prx4 activates c-Jun mediated AP-1 activation.
(A, B) Proteome profiler human phosphokinase array (A) and quantification of phosphorylated c-Jun levels (B). -, no
stimulation. +, serum stimulation. Compared to ShNT (+) cells, *p<0.05 (n = 4, t test). (C) Western blot of phosphorylated c-Jun after serum stimulation in A549 cells expressing ShNT, ShPrx4 or MycPrx4. (D) AP-1 luciferase
reporter assay in A549 cells with or without expression of ShRNAs or MycPrxs. Compared to either ShNT or vector
cells, *p<0.05 (n = 6, t test).

formation in soft agar in A549 cells (Figure 3A
and 3B). Moreover, knockdown of Prx1 or Prx4
also significantly repressed serum-induced cell
invasion in matrigel invasion assay (Figure 3C
and 3D). However, knockdown of Prx3 in A549
cells did not produce any effects on either colony formation or cell invasion. Therefore, our
data indicate that endogenously expressed
Prx1 and Prx4 are required for the integrity of
colony formation and invasion of A549 cells.
Overexpression of Prx1 or Prx4 in A549 cells
further enhances anchorage independent
colony formation and matrigel invasion
Next we asked whether ectopic expression of
Prxs in A549 cells may have an opposite effect
on colony formation and cell invasion. The coding regions of Human Prx1~4 were amplified
from HEK293T cells and cloned into a mammalian expression vector for protein expression
(Figure 4A). Stable cells overexpressing either
Myc tagged Prx1, 2, 3 or 4 were established
452

(Figure 4B). The phenotypical features of these
stable cells were then compared with parental
cells or control cells expressing an empty vector. We found that overexpression of MycPrx1
or MycPrx4 in A549 cells led to significant
increases in anchorage independent colony formation in soft agar (Figure 4C and 4D) and cells
invaded through matrigel (Figure 4E and 4F).
However, overexpression of either MycPrx2 or
MycPrx3 had no significant effects on colony
formation in soft agar as well as cell invasion
through matrigel. These data indicate that overexpression of Prx1 or Prx4, but not Prx2 or
Prx3, is able to further promote the anchorage
independent colony formation and matrigel
invasion of human lung cancer A549 cells.
Prx1 and Prx4 are required for the sustained
activation of AP-1 signaling
To understand the molecular basis of Prx1 and
Prx4 mediated cancer cell phenotype changes,
we examined the global phosphokinase signalAm J Cancer Res 2014;4(5):445-460
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Figure 6. Knockdown of Prx4 represses, whereas overexpression of MycPrx4 enhances tumor xenograft growth and
metastasis formation in mouse models in vivo. (A) Tumor growth curves of subcutaneously injected A549-ShNT,
ShPrx4 or MycPrx4 cells into SCID mice; (B, C) Images (B) and average weight (C) of primary tumors extracted from
injection sites 40 days post subcutaneous injection; (D) Lung tumor nodules found in SCID mice receiving tail vein
injection of A549-ShNT, ShPrx4 or MycPrx4 cells. Arrow heads indicated tumor nodules. Bar graph shows the average number of tumor nodules found in each experimental group. Compared to mice receiving ShNT cells, *p<0.05
(n = 9, t test).

ing changes mediated by Prx1 or Prx4 in A549
cells. This phosphokinase assay simultaneously detected the levels of 46 phosphorylated
proteins in duplicates, along with several predesigned negative and positive controls. To
identify proteins in which phosphorylation was
affected by the manipulation of either Prx1 or
Prx4 levels, multiple arrays were performed
using stable cells expressing ShNT, ShPrx1
(ShPrx4) or MycPrx1 (MycPrx4). The following
criteria were used to determine whether the
phosphorylation of a particular protein was
causally related with the levels of Prx1 or Prx4:
(1) compared with no stimulation, the levels of
phosphorylated protein in ShNT cells were
induced in the presence of serum containing
medium; (2) such induced activation was significantly repressed in ShPrx1 and ShPrx4 cells;
453

and (3) the phosphorylation can be further
enhanced in MycPrx1 and MycPrx4 cells.
Following this criteria, we identified that the levels of phosphorylated c-Jun was positively correlated with the levels of Prx1 or Prx4 in A549
cells (Figure 5A and 5B show results from
ShPrx4/MycPrx4 cells and similar results were
obtained from ShPrx1/MycPrx1 cells).
To confirm whether the activation/phosphorylation of c-Jun was indeed affected by depletion
or overexpression of Prx1 or Prx4, Western blot
was used to examine a serum-induced, timedependent phosphorylation of c-Jun in these
cells. Previous studies have shown that phosphorylation of Serine residues at 63 (Ser63)
and 73 (Ser73) determines the activation of
c-Jun, we thus examined the levels of phosAm J Cancer Res 2014;4(5):445-460
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phorylation at both sites with phospho-specific
antibodies. As shown in Figure 5C, ShPrx4 cells
showed a significant reduction in the phosphorylation levels of c-Jun at Ser63 and Ser73 residues at multiple time points after serum stimulation, and the levels of phosphorylation at both
residues in MycPrx4 cells were significantly
higher than those of ShNT cells (Figure 5C).
C-Jun is one of the major components of the
AP-1 transcription factor complex, whose activation contributes to multiple oncogenic processes including the stimulation of cell growth
and proliferation, cell invasion and metastasis
in various cancers. Therefore, we used an AP-1
luciferase reporter assay to test whether
manipulation of Prx1 or Prx4 levels had any
effect on the AP-1 mediated luciferase expression. As shown in Figure 5D, depletion of either
Prx1 or Prx4 in A549 cells led to the reduction
of the AP-1 luciferase activity, whereas depletion of Prx3 had no significant effect. Compared
with vector control cells, overexpression of
either MycPrx1 or MycPrx4 significantly stimulated the AP-1 luciferase reporter activity, but
overexpression of MycPrx2 or MyxPrx3 did not
affect the AP-1 luciferase activity. Therefore,
through maintaining and promoting the oncogenic AP-1 activation, expression of Prx1 and
Prx4 may contribute to the activation of AP-1
downstream signaling pathways that are critical for the malignancy of human lung cancer
cells.
Prx4 expression is required for tumor xenograft growth and metastasis formation in vivo
From cell culture studies we found that both
Prx1 and Prx4 were important for A549 cells to
grow in soft agar and to invade through matrigel. Previous studies have shown that downregulation of Prx1 in A549 cells led to the
reduced tumor xenograft growth and inhibition
of metastasis in mouse xenograft experiments
[27-29], which were consistent with our observation that knockdown of Prx1 led to reduced
malignant phenotype in A549 cells. However,
whether manipulating the levels of Prx4 in
A549 cells may affect tumor growth and metastasis in vivo has not been reported. Therefore,
we injected ShNT, ShSrx or MycPrx4 cells subcutaneously into groups of SCID mice to examine the ability of these cells to initiate/support
tumor growth in vivo. Compared with mice
injected with ShNT cells, subcutaneous tumor
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growth in mice injected with ShPrx4 cells was
significantly reduced, whereas tumor growth in
mice injected with MycPrx4 cells was significantly accelerated (Figure 6A). By the end of
the sixth week after subcutaneous injection, all
mice were euthanized and tumors were extracted from all mice, except one mouse in ShPrx4
group was free of tumor mass (Figure 6B).
Compared with tumors from mice receiving
ShNT cells, tumors from mice receiving MycPrx4
cells were much larger in size and heavier in
weight, while tumors from mice receiving
ShPrx4 cells were smaller in size and lighter in
weight (Figure 6B and 6C). These data suggest
that Prx4 positively contributes to tumor xenograft growth in vivo, which is consistent with
the observation that knockdown (or overexpression) of Prx4 leads to reduced (or
enhanced) colony formation of A549 cells in
soft agar.
The malignancy of cancer cells can be evaluated by their invasiveness and their capability of
initiating tumor metastasis in vivo. Based on
the observation that Prx4 is required for A549
cells to invade through matrigel in culture, we
hypothesized that Prx4 is also required for lung
cancer metastasis. To test this hypothesis,
A549 cells expressing ShNT, ShSrx or MycPrx4
were injected into the tail vein of SCID mice. At
8 weeks after injection, all mice were euthanized and mouse lung was extracted. Tumor
nodules with diameter equal or larger than 1.0
mm were identified microscopically (as indicated by the arrow heads in Figure 6D) and data
were analyzed. Compared with mice receiving
ShNT cells, there’s a significant reduction in the
number of tumor nodules in mice injected with
ShPrx4 cells; whereas a robust increase in the
number of tumor nodules was found in mice
injected with MycPrx4 cells (Figure 6D).
Therefore, knockdown of Prx4 in A549 cells
represses, whereas overexpression of MycPrx4
enhances, their ability to form lung tumor
metastasis in SCID mice.
Discussion
The Prx family of peroxidase provides critical
defense against oxidative stress through scavenging H2O2 and thus protects cells from oxidative damages. Therefore, the abundance of
Prxs is normally associated with attenuation of
oxidative stress and increased rate of cell sur-
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vival under various stress conditions. Due to an
essential secondary messenger function of
H2O2, Prxs are also considered as receptors for
cellular H2O2 and thus play multiple roles in
many physiological as well as pathological processes (for review, refer to [30]). In human lung
cancer, Prx1 is frequently identified as one of
the major cellular antioxidants that are preferentially expressed in cancer tissues but not in
normal lung epithelium or nonmalignant tumors
[13]. As a validated biomarker of lung adenocarcinoma [12, 31, 32], it mediates the prooxidants induced lung cancer cell growth and
invasion [33] and is required for human lung
cancer cells to grow as tumor xenograft and to
establish cancer metastasis in mice [27, 29].
Expression of Prx1 also confers human lung
cancer cells resistance to ionizing radiation
[27] and chemotherapeutic drugs [34]. Similar
to Prx1, Prx2 is also identified as aberrantly
increased in human lung cancer and its levels
are positively correlated with high-grade lung
carcinomas [32, 35], but the molecular basis of
Prx2 contribution to lung cancer development
has not been investigated. In breast cancer,
however, silencing of Prx2 leads to inhibition of
cancer cell growth and reduced formation of
lung metastasis in mice, which may be attributed to a novel function of Prx2 in regulating
cellular metabolism [36]. Unlike Prx1 or Prx2,
which are mainly localized in the cytosol, Prx3
is a mitochondria protein that is also overexpressed in human lung cancer [37]. Disruption
of Prx3 in mitochondria may function as a novel
mechanism of cellular response to cancer chemotherapeutics [38]. Prx4 is mainly localized in
the endoplasmic reticulum and is involved in
cellular inflammatory response [39]. However,
the role of Prx4 in human cancer is much less
studied compared with other 2-Cys Prxs. By
loss- and gain-of-function experiments, our
study reveals a critical role of Prx1 and Prx4 in
human lung cancer pathogenesis.
To date there are no genetic mutations identified in the Prx family of proteins that may associate with human diseases including cancer.
Therefore, the contribution of Prxs to human
cancer development is mainly resulted from
their aberrantly activated expression rather
than any genetic gain or loss of functional
mutations. Expression of Prxs can be regulated
at multiple levels, in which the activation of gene transcription plays a major role. Carcinogens

455

and tumor promoters, such as cigarette smoke,
asbestos, 4-(Methylnitrosamino)-1-(3-pyridyl)1-butanone (NNK), phorbol acetate and arsenate, have been shown to stimulate the expression of 2-Cys Prxs through activation of protein
kinase C, mitogen activated protein kinase
(MAPK) and P38MAPK pathways [32, 40, 41].
Hypoxia may also have some effect on the
expression of 2-Cys Prx expression, such as
activation of Prx 1 [42, 43]. Among all the transcription factors, nuclear related factor 2 (Nrf2)
plays a critical role in the activation of 2-Cys Prx
expression [30]. In our study we identified that
the levels of Prx1 and Prx4 were much higher in
human lung cancer cells. However, we did not
study the mechanisms of their up-regulation, in
the future it may be of interesting to understand why Prx1 and Prx4 were aberrantly activated in human lung cancer cells.
Due to the complicated role of H2O2 in mediating cell signaling, it is not surprising that the
function of Prxs is beyond the simple model of
acting as a pro-oncogenic factor. In fact, members of the Prx family may also have tumor suppressor activities. In particular, genomic loss of
Prx1 in mice leads to spontaneous tumor formation in multiple organs, which suggest that
Prx1 may function as a tumor suppressor [19].
Interestingly, the effect of Prx1 depletion in
mice may be strain dependent, since Prx1 null
mice established from another group are completely normal and free of tumors. Other 2-Cys
Prx null mice, including genomic knockout of
Prx2, 3 or 4 [44-47], are also phenotypically
normal and free of developmental defects.
However, one of the common features of Prx
knockout mice is that they are more sensitive
to oxidative stress induced cell death in general. In our study we found that overexpression of
Prx1 or Prx4 was able to further promote the
malignancy of human lung cancer cells. Systematic overexpression of Prx4 in mice, however, is not able to drive spontaneous tumorigenesis under laboratory conditions [48]. It is not
clear whether overexpression of both Prx1 and
Prx4 in mice is sufficient to drive de novo tumorigenesis in vivo. Transgenic mice that overexpress Prx3 also develop normally, and cells
from these mice have an increased resistance
to stress-induced cell death [49]. In the future,
it will be of interest to study whether overexpression of a single or any combination of 2-Cys
Prx in mice may affect the process of tumori-
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genesis or malignant progression of lung tumors induced by carcinogens, tumor promoters
or pre-existed, oncogenic mutations.
2-Cys Prxs are also involved in the activation of
various signaling pathways [30]. In mechanistic
study, our data demonstrated a critical role of
Prx1 and Prx4 in mediating the sustained activation of c-Jun, a major component of the AP-1
transcription factor complex. The molecular
mechanisms of why Prx1 and Prx4 are required
for c-Jun phosphorylation and the AP-1 mediated promoter activity still remain elusive. The
AP-1 activity is stimulated by numerous factors
including growth factors, chemokines and environmental stress. As a heterodimer, the AP-1
complex contains components of c-Fos, FosB,
FosL1 (Fra-1), FosL2 (Fra-2), c-Jun, JunB, JunD,
etc. Among them, c-Jun is activated by the
phosphorylation from upstream activated
kinases including MAPK, RSK and JNK kinase
systems [50]. Additionally, the transcriptional
activity of AP-1 complex is also regulated by
s-glutathionylation [51, 52], s-nitrosylation [53]
and oxidation [54]. Ref-1 is a redox sensitive
protein that activates the transcriptional activity of AP-1 either through a direct reduction of
the oxidized cysteine residue of c-Jun [55, 56],
or facilitating the nuclear translocation of thioredoxin [57-59]. In yeast, activation of Tpx1
(yeast homologue of Prx I) facilitates the reduction of oxidized cysteine in PAP1 (yeast homologue of c-Jun) and activates PAP1-dependent
gene transcription [60, 61]. Other possible
mechanisms have also been reported in the literature. For example, Prx1 may affect JNK
activities either through regulating the levels of
intracellular hydrogen peroxide [62], or directly
interacting with GSTpi-JNK complex to cause
the dissociation of JNK and subsequent activation [28]. It will be of interest to investigate
whether these potential mechanisms are also
applied in mammalian cells for Prx1 or Prx4 to
activate the AP-1 activity.
Activation of the AP-1 signaling is well documented in promoting the growth, proliferation,
invasion and metastasis of human lung cancer
cells [63, 64]. On one hand, activation of the
AP-1 complex can induce the expression of
downstream targeted genes including matrix
metalloproteinase MMP1, MMP2, MMP3 and
MMP9, osteonectin, autotaxin, etc [65, 66].
Expression of these genes promotes the
remodeling of extracellular matrix, epithelial456

mesenchymal transition and cell invasion. On
the other hand, the AP-1 complex can also function as transcriptional repressor to repress
genes that function as invasion suppressors
such as TSC-36, fibronectin, Krp1 and other
proteins [67, 68]. In principle, the expression of
these genes may be affected since we observed
a reduced activation of c-Jun phosphorylation
and an impaired AP-1 promoter activity in Prx1/
Prx4 knockdown cells. As a result, these gene
expression changes may explain the reduced
cell invasion in culture and metastasis formation in mice. Future understanding of how these
gene expression patterns are affected in
human lung cancer cells in response to different levels of 2-Cys Prxs may be informative.
Nevertheless, the contribution of 2-Cys Prxs to
the AP-1 signaling pathway is unambiguously
associated with cell invasion and metastasis of
human lung cancer, targeting 2-Cys Prxs to
develop novel therapeutic strategies in the
future may provide novel thoughts for cancer
prevention or drug discovery.
In summary, in this study we analyzed the
expression of 2-Cys Prxs in lung cancer, and
examined their levels of expression in a variety
of cell lines including human lung normal and
cancer cell lines. We found that Prx1 and Prx4
were preferentially expressed in cell lines established from human lung cancer including
SCC and adenocarcinoma. We demonstrated
that Prx1 and Prx4 (but not Prx3) were required
for human lung cancer A549 cells to form soft
agar colony and to invade through matrigel in
culture. Knockdown of Prx1 or Prx4 significantly
reduced the activation of c-Jun and thus
repressed AP-1 mediated promoter activity,
which may contribute to the changes of cancer
cell phenotype. In mouse xenograft models in
vivo, we found that knockdown of Prx4 reduced
subcutaneous tumor growth and blocked
metastasis formation. Furthermore, overexpression of Prx1 or Prx4 further enhanced the
malignancy of A549 cells in culture and in
mouse xenografts in vivo. Our data provide an
in-depth understanding of the contribution of
Prx1 and Prx4 to lung cancer development and
provide valuable information for future development of therapeutic methods that targeting
2-Cys Prxs.
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